Prior COVID-19 infection among newly diagnosed tuberculosis patients in a tertiary care center in Tehran: A case-control study.
COVID‐19
Tocilizumab
corticosteroid
prevention
pulmonary
reactivation
risk
tuberculosis
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
14
04
2024
received:
01
12
2023
accepted:
05
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
28
5
2024
Statut:
ppublish
Résumé
To assess the risk of developing pulmonary tuberculosis (TB) in accordance with prior history of COVID-19 infection. Since the advent of the COVID-19 pandemic much discussion has been had on the possible role it might play on global efforts to combat TB; most, focusing on the pandemic's impact on health care systems' capabilities to manage TB cases. Mechanisms have also been proposed by which the COVID-19 infection may directly affect individuals' chance of developing TB infection. Cases have been reported with a history of COVID-19 infection preceding a diagnosis of TB, evidencing its possible role as a risk factor for the disease. A case-control study was conducted enrolling patients diagnosed with pulmonary TB in the absence of major risk factors previous history of TB, (HIV) human immunodeficiency virus infection), end-stage renal disease, organ transplants, and use of immunosuppressive agents) for developing TB. Each patient was age and sex matched with one healthy control. Data regarding prior COVID-19 infection, diabetes, and smoking status as well as the use of corticosteroids and Tocilizumab for the treatment of COVID-19 infection was obtained. Bivariate analysis was conducted and variables with a likely association with TB status were entered in a multivariate model. Bivariate analysis demonstrated a significant relationship between prior COVID-19 infection and TB (95% confidence interval = 1.1-22.8, odds ratio [OR] = 5). Among other variables the severity of COVID-19 infection was found to have a likely association with TB status (p = .125). In a multivariate model, prior COVID-19 infection per se, was not found to be significantly associated with TB (p = .12, OR = 4.5). There seems to be an association between prior history of COVID-19 and a future diagnosis of TB partially linked to the severity of disease. The findings of the current study may serve as a basis for further studies to determine the need for and efficacy of measures to follow-up COVID-19 patients at an increased risk for developing TB.
Sections du résumé
OBJECTIVE
OBJECTIVE
To assess the risk of developing pulmonary tuberculosis (TB) in accordance with prior history of COVID-19 infection.
BACKGROUND
BACKGROUND
Since the advent of the COVID-19 pandemic much discussion has been had on the possible role it might play on global efforts to combat TB; most, focusing on the pandemic's impact on health care systems' capabilities to manage TB cases. Mechanisms have also been proposed by which the COVID-19 infection may directly affect individuals' chance of developing TB infection. Cases have been reported with a history of COVID-19 infection preceding a diagnosis of TB, evidencing its possible role as a risk factor for the disease.
METHODS
METHODS
A case-control study was conducted enrolling patients diagnosed with pulmonary TB in the absence of major risk factors previous history of TB, (HIV) human immunodeficiency virus infection), end-stage renal disease, organ transplants, and use of immunosuppressive agents) for developing TB. Each patient was age and sex matched with one healthy control. Data regarding prior COVID-19 infection, diabetes, and smoking status as well as the use of corticosteroids and Tocilizumab for the treatment of COVID-19 infection was obtained. Bivariate analysis was conducted and variables with a likely association with TB status were entered in a multivariate model.
RESULTS
RESULTS
Bivariate analysis demonstrated a significant relationship between prior COVID-19 infection and TB (95% confidence interval = 1.1-22.8, odds ratio [OR] = 5). Among other variables the severity of COVID-19 infection was found to have a likely association with TB status (p = .125). In a multivariate model, prior COVID-19 infection per se, was not found to be significantly associated with TB (p = .12, OR = 4.5).
CONCLUSIONS
CONCLUSIONS
There seems to be an association between prior history of COVID-19 and a future diagnosis of TB partially linked to the severity of disease. The findings of the current study may serve as a basis for further studies to determine the need for and efficacy of measures to follow-up COVID-19 patients at an increased risk for developing TB.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1275Informations de copyright
© 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
World Health Organization. WHO Coronavirus (COVID‐19) Dashboard. 2023. https://covid19.who.int
World Health Organization. Global expenditure on health: Public spending on the rise? 2021. https://www.who.int/publications/i/item/9789240041219
World Health Organization (WHO). Global tuberculosis report 2021. 2021. https://www.who.int/publications/i/item/9789240037021
Izzo C, Monica A, De Matteis G, et al. Not only COVID‐19: prevalence and management of latent mycobacterium tuberculosis infection in three penitentiary facilities in Southern Italy. Healthcare (Basel). 2022;10(2):386. doi:10.3390/healthcare10020386
de Paus RA, van Crevel R, van Beek R, et al. The influence of influenza virus infections on the development of tuberculosis. Tuberculosis. 2013;93(3):338‐342. doi:10.1016/j.tube.2013.02.006
Barry M. Prevalence of latent tuberculosis infection in the Middle East and north Africa: a systematic review. Pulm Med. 2021;2021:1‐12. doi:10.1155/2021/6680651
Zellweger JP, Sotgiu G, Corradi M, Durando P. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Med Lav. 2020;111(3):170‐183. doi:10.23749/mdl.v111i3.9983
World Health Organization (WHO). Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization; 2018. https://iris.who.int/handle/10665/260233
World Health organization (WHO). Global tuberculosis report 2023. 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
Geneva: World Health organization (WHO). Global tuberculosis report 2022. 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
Mehraeen E, Salehi MA, Behnezhad F, Moghaddam HR, SeyedAlinaghi S. Transmission modes of COVID‐19: a systematic review. Infect Diso Drug Targ. 2021;21(6):e170721187995. doi:10.2174/1871526520666201116095934
Visca D, Ong CWM, Tiberi S, et al. Tuberculosis and COVID‐19 interaction: a review of biological, clinical and public health effects. Pulmonology. 2021;27(2):151‐165. doi:10.1016/j.pulmoe.2020.12.012
Mohareb AM, Rosenberg JM, Bhattacharyya RP, et al. Preventing infectious complications of immunomodulation in COVID‐19 in foreign‐born patients. J Immig Minor Health. 2021;23(6):1343‐1347. doi:10.1007/s10903-021-01225-4
Saunders MJ, Evans CA. COVID‐19, tuberculosis and poverty: preventing a perfect storm. Eur Respir J. 2020;56(1):2001348. doi:10.1183/13993003.01348-2020
Pathak L, Gayan S, Pal B, et al. Coronavirus activates an altruistic stem cell‐mediated defense mechanism that reactivates dormant tuberculosis: implications in coronavirus disease 2019 pandemic. Am J Pathol. 2021;191(7):1255‐1268. doi:10.1016/j.ajpath.2021.03.011
Tadolini M, Codecasa LR, García‐García J‐M, et al. Active tuberculosis, sequelae and COVID‐19 co‐infection: first cohort of 49 cases. Eur Respir J. 2020;56(1):2001398. doi:10.1183/13993003.01398-2020
The TB/COVID‐19 Global Study Group. Tuberculosis and COVID‐19 co‐infection: description of the global cohort. Eur Respir J. 2022;59(3):2102538. doi:10.1183/13993003.02538-2021
Easton AV, Salerno MM, Trieu L, et al. Cohort study of the mortality among patients in New York city with tuberculosis and COVID‐19, March 2020 to June 2022. PLOS Glob Public Health. 2023;3(4):e0001758. doi:10.1371/journal.pgph.0001758
Aguillón‐Durán GP, Prieto‐Martínez E, Ayala D, et al. COVID‐19 and chronic diabetes: the perfect storm for reactivation tuberculosis? a case series. J Med Case Reports. 2021;15(1):621. doi:10.1186/s13256-021-03193-7
Colby S, Shah R. TB reactivation following COVID‐19 infection. Chest. 2022;162(4):A329. doi:10.1016/j.chest.2022.08.255
Iovino M, Caruso M, Corvino A, et al. Latent tuberculosis reactivation in the setting of SARS‐Cov‐2 infection: the analysis of the radiologic features that help the diagnosis. Radiol Case Rep. 2022;17(4):1309‐1312. doi:10.1016/j.radcr.2022.01.063
Leonso AA, Brown K, Prol R, Rawat S, Khunger A, Bromberg R. A rare case of latent tuberculosis reactivation secondary to a COVID‐19 infection. Infect Dis Rep. 2022;14(3):446‐452. doi:10.3390/idr14030048
Noori M, Younes I, Latif A, et al. Reactivation of tuberculosis in the setting of COVID‐19 infection. Cureus. 2022;14(3):23417. doi:10.7759/cureus.23417
Njekwa K, Muyoyeta M, Mulenga B, Chisenga CC, Simuyandi M, Chilengi R. Superimposed pulmonary tuberculosis (PTB) in a 26‐year‐old female with no underlying co‐morbidities recovering from COVID‐19‐case report. Trop Med Infect Dis. 2023;8(5):268. doi:10.3390/tropicalmed8050268
Alemu A, Bitew ZW, Seid G, et al. Tuberculosis in individuals who recovered from COVID‐19: a systematic review of case reports. PLoS One. 2022;17(11):e0277807. doi:10.1371/journal.pone.0277807
Stevenson MA. Sample Size Estimation in Veterinary Epidemiologic Research. Front Vet Sci. 2021:7. doi:10.3389/fvets.2020.539573
Zamani M, Poustchi H, Mohammadi Z, et al. Seroprevalence of SARS‐CoV‐2 antibody among urban Iranian population: findings from the second large population‐based cross‐sectional study. BMC Public Health. 2022;22(1):1031. doi:10.1186/s12889-022-13464-7
Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10. doi:10.1038/emi.2016.10
Park SW, Song JW, Shim TS, et al. Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis. J Korean Med Sci. 2012;27(8):896‐900. doi:10.3346/jkms.2012.27.8.896
Shachor Y, Schindler D, Siegal A, Lieberman D, Mikulski Y, Bruderman I. Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax. 1989;44(2):151‐153. doi:10.1136/thx.44.2.151
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American thoracic society/infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111‐115. doi:10.1093/cid/ciw778
American College of Emergency Physicians. ACEP COVID‐19 Field Guide. 2021. https://www.acep.org/corona/covid-19-field-guide
Sadeghi K, Poorolajal J, Doosti‐Irani A. Prevalence of modifiable risk factors of tuberculosis and their population attributable fraction in Iran: a cross‐sectional study. PLoS One. 2022;17(8):e0271511. doi:10.1371/journal.pone.0271511
Sullivan KM, Dean A, Soe MM. On Academics: OpenEpi: a web‐based epidemiologic and statistical calculator for public health. Public Health Rep. 2009;124(3):471‐474. doi:10.1177/003335490912400320
IBM Corp. IBM SPSS Statistics for Windows (Version 25) [Computer software]. IBM Corp, 2017.
Srivastava S, Jaggi N. TB positive cases go up in ongoing COVID‐19 pandemic despite lower testing of TB: an observational study from a hospital from Northern India. Indian J Tuberc. 2022;69(2):157‐160. doi:10.1016/j.ijtb.2021.04.014
Pozdnyakov A, Jin A., Bader M. Reactivation of pulmonary tuberculosis in a patient with COVID‐19: case report and review of literature. Infect Dis Clin Pract (Baltim Md). 2021;29(6):e468‐e470. doi:10.1097/ipc.0000000000001032
Lai C‐C, Lee M‐T G, Lee S‐H, Lee S‐H, Chang S‐S, Lee C‐C. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis. 2015;19(8):936‐942. doi:10.5588/ijtld.15.0031
Gopalaswamy R, Subbian S. Corticosteroids for COVID‐19 therapy: potential implications on tuberculosis. Int J Mol Sci. 2021;22(7):3773. doi:10.3390/ijms22073773
Tapela K, Ochieng' Olwal C, Quaye O. Parallels in the pathogenesis of SARS‐CoV‐2 and M. tuberculosis: a synergistic or antagonistic alliance? Future Microbiol. 2020;15:1691‐1695. doi:10.2217/fmb-2020-0179
Tamuzi JL, Ayele BT, Shumba CS, et al. Implications of COVID‐19 in high burden countries for HIV/TB: a systematic review of evidence. BMC Infect Dis. 2020;20(1):744. doi:10.1186/s12879-020-05450-4
Riou C, Du Bruyn E, Stek C, et al. Relationship of SARS‐CoV‐2‐specific CD4 response to COVID‐19 severity and impact of HIV‐1 and tuberculosis coinfection. J Clin Invest. 2021;131(12):e149125. doi:10.1172/jci149125
Ward JD, Cornaby C, Schmitz JL. Indeterminate QuantiFERON gold plus results reveal deficient interferon gamma responses in severely ill COVID‐19 patients. J Clin Microbiol. 2021;59(10):0081121. doi:10.1128/jcm.00811-21
Siranart N, Sowalertrat W, Sukonpatip M, Suwanpimolkul G, Torvorapanit P. First case series and literature review of coronavirus disease 2019 (COVID‐19) associated pulmonary tuberculosis in Southeast Asia: challenges and opportunities. J Infect Pub Health. 2023;16(1):80‐89. doi:10.1016/j.jiph.2022.11.029
Wang Y, Xu J, Wang Y, et al. Prevalence of comorbid tuberculosis amongst COVID‐19 patients: a rapid review and meta‐analysis. Int J Clin Pract. 2021;75(11):e14867. doi:10.1111/ijcp.14867
MacLean EL, Villa‐Castillo L, Espinoza‐Lopez O, et al. Integrating tuberculosis and COVID‐19 molecular testing in Lima, Peru: a cross‐sectional, diagnostic accuracy study. Lancet Microbe, 2023. doi:10.1016/s2666-5247(23)00042-3
McQuaid CF, Vassall A, Cohen T, et al. The impact of COVID‐19 on TB: a review of the data. Int J Tuberc Lung Dis. 2021;25(6):436‐446. doi:10.5588/ijtld.21.0148
Maciel ELN, Gonçalves E, Dalcolmo MMP, et al. Tuberculosis and coronavirus: what do we know? Epidemiol Serv Saude. 2020;29(2):e2020128. doi:10.5123/s1679-49742020000200010
Sanju Sv C, Srinivasapura Venkateshmurthy N, Nair D, et al. What proportion of new tuberculosis patients has a history of household tuberculosis exposure? A cross‐sectional study from udupi district, south India. Trop Med Infect Dis. 2019;4(4):133. doi:10.3390/tropicalmed4040133